Filing Flows › Conmed (CNMD) › Q3 2026 › vs Q3 2025
Conmed (CNMD) Q3 2026 vs Q3 2025 (year over year)
Conmed's revenue fell $2.4M (-0.7%) from $338M in Q3 2025 to $336M in Q3 2026. The biggest changes: General Surgery −$13.0M (-7%); Orthopedic Surgery +$10.6M (+8%). Gross margin 56.4% against 49.2% (+7.2 pts).
Conmed, Q3 2026: revenue $336M (-0.7% year over year), operating margin 11.1%, net earnings $19.8M, operating cash flow $49.4M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 56.4% | 49.2% | +7.2 pts |
| Operating margin | 11.1% | 3.5% | +7.6 pts |
| Net margin | 5.9% | 0.8% | +5.1 pts |
| Free cash flow margin | 13.9% | 14.4% | -0.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| General Surgery | $187M | $200M | −$13.0M | -7% |
| Orthopedic Surgery | $149M | $138M | $10.6M | +8% |
| Revenue | $336M | $338M | −$2.4M | -0.7% |
| Gross profit | $189M | $166M | $23.0M | +14% |
| Cost of revenue | $146M | $172M | −$25.4M | -15% |
| Operating profit | $37.1M | $11.9M | $25.3M | +213% |
| Operating expenses | $152M | $154M | −$2.2M | -1% |
| Pre-tax earnings | $26.0M | $4.3M | $21.7M | +509% |
| Other expense, net | $11.1M | $7.6M | $3.5M | +46% |
| Research & development | $15.6M | $13.9M | $1.7M | +12% |
| SG&A | $136M | $140M | −$3.9M | -3% |
| Net earnings | $19.8M | $2.9M | $16.9M | +592% |
| Income tax | $6.2M | $1.4M | $4.8M | +339% |
| Depreciation & amortization | $12.8M | $13.1M | −$295K | -2% |
| Share-based compensation | $5.9M | $4.6M | $1.3M | +29% |
| Working capital & other | $10.9M | $33.2M | −$22.2M | -67% |
| Operating cash flow | $49.4M | $53.7M | −$4.3M | -8% |
| Free cash flow (OCF − capex) | $46.7M | $48.5M | −$1.8M | -4% |
| Capital expenditures | $2.7M | $5.2M | −$2.5M | -48% |
Questions
How much did Conmed's revenue grow year over year in Q3 2026?
Conmed's revenue fell $2.4M (-0.7%) from $338M in Q3 2025 to $336M in Q3 2026.
What drove Conmed's revenue change in Q3 2026?
General Surgery −$13.0M (-7%); Orthopedic Surgery +$10.6M (+8%).